• Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    Denmark Germany Italy The Netherlands Norway

  • Effect of Acetazolamide Added to Standard Therapy on Weight Reduction and Symptom Relief in Patients with Heart Failure

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Long‑Term Effects of Sirolimus on Volume and Color of Port‑Wine Stain in Patients with Vascular Malformation Undergoing Surgery and Laser Therapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Evaluation of gaxilose (LacTEST 0.45 g) as a marker of intestinal barrier integrity in patients with celiac disease

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study of Topical Chloramphenicol vs Topical Ciprofloxacin for Treating Otorrhea in Adults with Chronic Suppurative Otitis Media

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    Spain

  • Effect of High‑Dose Thiamine Hydrochloride on Fatigue in Rheumatoid Arthritis Patients: Randomized, Double‑Blind, Placebo‑Controlled Trial

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark

  • Phase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    Italy

  • Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    France

powered by